1
|
Griffin KH, Thorpe SW, Sebastian A, Hum NR, Coonan TP, Sagheb IS, Loots GG, Randall RL, Leach JK. Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening. Proc Natl Acad Sci U S A 2023; 120:e2302101120. [PMID: 37729195 PMCID: PMC10523456 DOI: 10.1073/pnas.2302101120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 08/17/2023] [Indexed: 09/22/2023] Open
Abstract
Osteosarcoma (OS) is the most common primary malignant bone cancer in children and adolescents. While numerous other cancers now have promising therapeutic advances, treatment options for OS have remained unchanged since the advent of standard chemotherapeutics and offer less than a 25% 5-y survival rate for those with metastatic disease. This dearth of clinical progress underscores a lack of understanding of OS progression and necessitates the study of this disease in an innovative system. Here, we adapt a previously described engineered bone marrow (eBM) construct for use as a three-dimensional platform to study how microenvironmental and immune factors affect OS tumor progression. We form eBM by implanting acellular bone-forming materials in mice and explanting the cellularized constructs after 8 wk for study. We interrogate the influence of the anatomical implantation site on eBM tissue quality, test ex vivo stability under normoxic (5% O2) and standard (21% O2) culture conditions, culture OS cells within these constructs, and compare them to human OS samples. We show that eBM stably recapitulates the composition of native bone marrow. OS cells exhibit differential behavior dependent on metastatic potential when cultured in eBM, thus mimicking in vivo conditions. Furthermore, we highlight the clinical applicability of eBM as a drug-screening platform through doxorubicin treatment and show that eBM confers a protective effect on OS cells that parallel clinical responses. Combined, this work presents eBM as a cellular construct that mimics the complex bone marrow environment that is useful for mechanistic bone cancer research and drug screening.
Collapse
Affiliation(s)
- Katherine H. Griffin
- Department of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA95817
- School of Veterinary Medicine, University of California, Davis, CA95616
| | - Steven W. Thorpe
- Department of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA95817
| | - Aimy Sebastian
- Physical and Life Sciences, Lawrence Livermore National Laboratory, Livermore, CA94550
| | - Nicholas R. Hum
- Physical and Life Sciences, Lawrence Livermore National Laboratory, Livermore, CA94550
| | - Thomas P. Coonan
- Department of Biomedical Engineering, University of California, Davis, CA95616
| | - Isabel S. Sagheb
- Department of Biomedical Engineering, University of California, Davis, CA95616
| | - Gabriela G. Loots
- Department of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA95817
- Physical and Life Sciences, Lawrence Livermore National Laboratory, Livermore, CA94550
| | - R. Lor Randall
- Department of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA95817
| | - J. Kent Leach
- Department of Orthopaedic Surgery, University of California Davis Health, Sacramento, CA95817
- Department of Biomedical Engineering, University of California, Davis, CA95616
| |
Collapse
|